A few years ago, Andrew W. Lo from the MIT Sloan School of Management gave a lengthy talk at a meet-and-greet for prospective students of the Master of Finance program.
Keep Reading →
May 23 - News
Reaching the coveted $1 billion mark in annual sales is no small feat for a drug.
Keep Reading →
May 8 - News
When a new strategy hits the Street and it gains assets at a significant rate over a very short period of time, the ability of this new program to absorb the new money is quickly...
Keep Reading →
May 2 - News
Amgen, Inc. (NASDAQ:AMGN) stock has been on a bit of a roller coaster lately.
Keep Reading →
May 1 - News
A failing heart is a lot like a glass Heinz Ketchup bottle. Squeezing the bottle isn't very efficient, so you smack that strategically placed '57,' and still no condiment. ...
Keep Reading →
April 29 - News
When it comes to biotechs, Amgen, Inc. (NASDAQ:AMGN) qualifies for the senior citizen discount.
Keep Reading →
April 24 - News
On Tuesday, Amgen, Inc. (NASDAQ:AMGN) will release its latest quarterly results.
Keep Reading →
April 21 - News
Shares of Amgen, Inc. (NASDAQ:AMGN) have returned over 65% in the past year; 109% if dividends are included. The S&P 500 has returned just over 13%.
Keep Reading →
April 18 - News
Another day, another set of fresh all-time highs for the major biotechnology ETFs.
Keep Reading →
April 16 - Stock Analysis
Two high-flying biotech stocks of late are NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) .
Keep Reading →
April 16 - News
Editor's Note: Related tickers: Theravance Inc (NASDAQ:THRX), VIVUS, Inc. (NASDAQ:VVUS), Amgen, Inc.
Keep Reading →
April 15 - News
Targeting psoriasis, rheumatoid arthritis, and other immune diseases has created some massive markets over the last decade.
Keep Reading →
April 8 - News
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, clinical-stage drug development company ...
Keep Reading →
April 8 - News
The biotechnology sector can be a land of immense spoils and incredible heartbreak.
Keep Reading →
April 7 - News
What doesn't J&J produce? From pharmaceuticals to consumer care goods to medical devices, this major medical player has it all.
Keep Reading →
April 7 - News
As I noted five weeks ago, cancer statistics are both staggering and disappointing.
Keep Reading →
April 2 - News
The drug development field is a potentially lucrative, although always dangerous area for small companies and their investors to participate in.
Keep Reading →
March 27 - News
In this series, we'll highlight four companies in an industry, and compare their "cash king margins" over time, trying to determine which has the greatest likelihood of putting...
Keep Reading →
March 27 - News
For the last several years, Merck & Co., Inc.
Keep Reading →
March 26 - News
With interest rates still sitting near record lows, investors looking for current income have been forced to move from fixed-income positions and into stocks to find yield.
Keep Reading →
March 17 - News
LONDON -- You have only a few weeks to use your ISA allowance before the April 5 deadline, so don't fluff this great tax-saving opportunity.
Keep Reading →
March 15 - News
After the stomach-churning market drop of several years ago and the equally impressive climb back from 2009's lows, many investors are feeling a bit exhausted.
Keep Reading →
March 13 - News
In order to be successful in investing, just pick a great company and stick with it through ups and downs. That is what Charlie Munger often advises investors to do.
Keep Reading →
March 13 - News
The Motley Fool recently published its list of The 25 Best Companies in America and while Bristol-Myers Squibb Co.
Keep Reading →
March 12 - News
Cancer just might be one of the scariest words in the English language. What goes through your mind when you hear that someone close to you has cancer? Sadness, probably.
Keep Reading →
March 11 - News
You won't often hear me say this, but it's a pretty quiet week on the health-care front.
Keep Reading →
March 10 - News
For three days running, the Dow Jones Industrials have set new all-time record highs.
Keep Reading →
March 8 - News
The early bird gets the worm. Business gurus might not use that old phrase, but many of them tout the principle behind it.
Keep Reading →
March 6 - News
Investors are always trying to find the right balance between risk andreward.
Keep Reading →
March 4 - News
Celgene Corporation (NASDAQ:CELG) has good news -- and it has bad news.
Keep Reading →
March 4 - News
Celgene Corporation (NASDAQ:CELG) shareholders didn't have to wait long for good news in 2013. On Jan.
Keep Reading →
February 26 - News
At the end of last year, I proclaimed Omontys -- an erythropoiesis-stimulating agent, or ESA, that aids in the formation of red blood cells -- as one of my 10 drugs approved by...
Keep Reading →
February 25 - News
Look out below Affymax, Inc. (NASDAQ:AFFY) investors.
Keep Reading →
February 25 - News
Merck & Co., Inc. (NYSE:MRK) has to more heavily rely on top selling pharmaceuticals now that Singulair's off patent.
Keep Reading →
February 22 - News
Following the close of the bell yesterday, ABIOMED released a statement announcing that U.S.
Keep Reading →
February 21 - News
Stock buybacks are generally considered a bullish signal on Wall Street.
Keep Reading →
February 21 - News
Celgene Corporation (NASDAQ:CELG) announced on Wednesday a $600 million deal to buy a stake in a growing biotech with several successful products on the market and a strong pipeline...
Keep Reading →
February 20 - News
One thing's for sure: You'll never discover truly great investments unless you actively look for them.
Keep Reading →
February 20 - News
When the word "biotechnology" gets thrown around in the pharmaceutical industry, it often implies the biomanufacturing of biologic drugs, such as therapeutic proteins.
Keep Reading →
February 20 - News
Shares of Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) have risen by more than 35% since last Thursday.
Keep Reading →
February 19 - News
The biggest biopharmaceutical companies blazed trails and lifted portfolios last year.
Keep Reading →
February 18 - News
When you think about a cutting-edge, one-foot-in-the-future biotech company, no one would blame you for skipping over Amgen, Inc. (NASDAQ:AMGN).
Keep Reading →
February 18 - News
Research firm Decision Resources predicts that the rheumatoid arthritis market will modestly grow to $15 billion in the next decade.
Keep Reading →
February 18 - News
At The Motley Fool, we poke plenty of fun at Wall Street analysts and their endless cycle of upgrades, downgrades, and "initiating coverage at neutral." Today, we'll show you ...
Keep Reading →
February 14 - News
The biotechnology industry is one of the most attractive industries for investors primarily due to its high returns.
Keep Reading →
February 14 - News
Johnson & Johnson (NYSE:JNJ) may offer well-known personal care products such as Listerine and Neutrogena, but it also boasts an impressive portfolio of market leading therapeutic...
Keep Reading →
February 14 - News
How much is trustworthiness actually worth? That somewhat strange thought entered my brain recently after reviewing the latest Harris Physician Pulse Survey.
Keep Reading →
February 13 - News
Sometimes an analyst issues a revised outlook or changes his/her rating, but does not inform investors of the reasons behind the call.
Keep Reading →
February 12 - News
One strategy that has proven to be effective over time in determining whether a stock is moving higher is insider accumulation, due to one simple reason.
Keep Reading →
February 12 - Insider Trading
